TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: cognitive markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: neuroimaging markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MPI levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antral hyperplastic polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: carcinoid tumor detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: antral mucosa atrophy increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: sinus rhythm at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of postoperative intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mortality at 12 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Mean Orgogozo scale score after 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Barthel Index score at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥3-step DR improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of PDR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near‐Far Quickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye‐Hand Coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Go/No Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood lactate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TcPO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioavailability of melagatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma concentration of melagatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol acrophase timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean change in TOI scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in mean Gastric Cancer Subscale values
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: risk reduction of death
Endpoint domain: Mortality/survival
Primary endpoint: risk reduction of progression
Endpoint domain: Mortality/survival
Primary endpoint: Identification of hypercortisolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diagnosis of secondary adrenal insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Karnofski score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission from major depressive disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deaths related to drug toxicity
Endpoint domain: Mortality/survival
Primary endpoint: Proceeded to surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of nocturnal hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: amygdala connectivity with the right prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: amygdala connectivity with the insula and dorsal PCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Menstrual Blood Loss (MBL) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pleasure and interest
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Platelet count at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall response rate at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulated dose of opioid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marijuana craving (MCQ-Compulsivity scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline of serum HBV DNA from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic response rates at 96 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic breakthrough rates
Endpoint domain: Adverse events/effects
Primary endpoint: grasp aperture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reaching time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hostility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain reported on the visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Need for supplemental anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Function in instrumental activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Interval from gel insertion to vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meperidine as analgesic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased muscular strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: improved pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ability to perform tasks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean change in HAM-A scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained response rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resolution of pelvic girdle pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: quality of life 1 year postoperatively
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ACR20 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF36 physical component scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Expression of epidermal activation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of dermal T cell infiltrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of VEGFR2 and VEGFR3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion at risk for early aseptic loosening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visual recognition memory impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of systolic BP measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of diastolic BP measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Structured clinical examination score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slow-wave activity (SWA) of the electroencephalogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum transferrin receptor concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median hTRAb concentration after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Progression of GO symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Stent patency rate at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stent patency rate at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total adverse event rate after stent deployment
Endpoint domain: Adverse events/effects
Primary endpoint: Breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean differences in measured sound level (SL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance covered in the 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: St George's Respiratory Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement in mood and behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: speech skills improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: renal dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Erectile Function domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Esteem subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of chronic lung disease
Endpoint domain: Adverse events/effects
Primary endpoint: Length of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in clinical score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean oxygen requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: standard deviation in normal-to-normal R-R intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glutathione peroxidase levels increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Superoxide dismutase levels increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of pneumonia/serious febrile illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diarrhea/growth faltering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year SVG failure
Endpoint domain: Mortality/survival
Primary endpoint: 5-year composite of death, MI, or revascularization
Endpoint domain: Mortality/survival
Primary endpoint: 5-year death or MI
Endpoint domain: Mortality/survival
Primary endpoint: Free-ICU days in 28 days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Free-organ-dysfunction days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: reduction in respiratory illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: pre- and posttest scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rate of constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: salivary cotinine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in maternal problem alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: repeated incidents of physical partner violence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measure of poor mental health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent angina, MI or death
Endpoint domain: Mortality/survival
Primary endpoint: need for coronary revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: minor hemorrhagic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Serum T3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean peak aqueous concentration of ketorolac 0.45%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective perception of cognitive effects
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: risk of death and nonfatal cardiovascular outcomes
Endpoint domain: Mortality/survival
Primary endpoint: femoral tunnel length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Stress-induced regional perfusion defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete response to study medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median nausea scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cross-sectional Area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of blood flow to ischemic zones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Malassezia numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in clinical scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and feasibility of advance provision of pills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC folate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma folate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma total homocysteine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tunnel enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: spectacle procurement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: satisfaction with spectacles
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of High-altitude pulmonary edema (HAPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of PTSD at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: slowing disease progression in ALS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vancouver scar scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual analog scale of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success at 2-year follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastroesophageal reflux
Endpoint domain: Adverse events/effects
Primary endpoint: dual-10 Meter Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dual-Timed Up-and-Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities-specific Balance Confidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static and dynamic VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stool and fluid cleansing ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: NODAT occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HIV‐1 RNA levels <50 copies per milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of CD3+CD4+ and CD4+/CD8+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: readmission rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients requiring morphine administration
Endpoint domain: Adverse events/effects
Primary endpoint: Inflammatory cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in mutual understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in perceived quality of care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean adenoidal obstruction of the choanae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: obstructive symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasal obstruction symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCL28 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: enamel resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful L-CRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neovascular complications
Endpoint domain: Adverse events/effects
Primary endpoint: necroinflammatory activity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: fibrosis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in Left Ventricular Mass (LVM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Central Pulse Pressure (PP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bacteriologic cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal adverse events severity
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of condomless sexual intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of sexual intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological attachment percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory extent and cellularity grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative nausea (PONV) at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of nausea (measured by VAS 100 mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug dependence profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: livebirth
Endpoint domain: Mortality/survival
Primary endpoint: Long-term concurrent stimulant-opioid use prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force required to fracture the roots vertically
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kt/V measurement increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of facility Kt/V goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from catheters to fistulas/grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: coronary constriction response to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: H-reflex amplitude during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score difference pre- and post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rates of external sty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPI intervention rate per 100 high-dose PPI prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost savings attributable to the prompt
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: New cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mild and moderate hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: ABL reintroduction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABL reintroduction X-ray exposure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total X-ray exposure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal obstruction VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fat oxidation during steady-state cycling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Power output during HIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time trial performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes